Genetic and Genomic Factors Shaping Prostate Cancer in American Men
Official title: Genetic and Genomic Variation in Prostate Cancer
Funded at Dana-Farber Cancer Inst · NIH-11535327 · Data updated 2026-11-12
This grant looks at how inherited genes and tumor DNA influence the risk and behavior of prostate cancer in American men, with a focus on diversity and ancestry.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 7, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $55,368 |
| NIH project number | 3R01CA259200-05S4 |
| Project ID | NIH-11535327 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are men at risk for or diagnosed with prostate cancer, particularly those with African ancestry or diverse genetic backgrounds.
✕Less likely to help
Patients without access to genomic testing or not involved in targeted precision medicine approaches may see limited immediate benefit.
What this research studies
If you have or are at risk for prostate cancer, this project studies how a person’s genetic makeup and the tumor’s DNA changes may affect how the cancer starts and grows. Researchers will analyze thousands of genetic variants and tumor profiles to understand why prostate cancer is different among individuals, especially among men of African descent. The work aims to translate genetic findings into better, more personalized approaches to diagnosis and treatment. The findings could help reduce misdiagnoses and improve how doctors tailor care to each patient’s genetic background.
Why it matters
Potential benefit: A better understanding of genetic risk and tumor biology could lead to more accurate risk assessment and personalized treatment options for prostate cancer.
How similar studies have gone: Previous studies have shown that germline and tumor genomics influence prostate cancer risk and behavior, supporting the approach, though full translation to diverse populations remains ongoing.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Rebbeck, Timothy Richard — Dana-Farber Cancer Inst
- Study coordinator: Rebbeck, Timothy Richard
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.